Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges

There are just two chimeric antigen receptor T-cell (CAR-T) therapies approved in the US, but dozens of companies already are clamoring to bring the next generation of CAR-T products to the market that address novel targets, improve toxicity and tackle the field's other big challenges.

Poseida Therapeutics Inc. and Celyad SA spoke with Scrip about their first products in the clinic and initial results in a handful of patients, but the vast majority of CAR-T data at the American Association for Cancer Research (AACR) meeting April 14-18 in Chicago was preclinical research for emerging CAR-T candidates and novel constructs